May 26 - Alabama’s medical regulator has issued a clear directive to clinicians regarding so-called research-grade peptides, advising that these substances should not be prescribed, dispensed or administered in clinical practice. The Board of Medical Examiners emphasized that these products have not been tested or reviewed by the U.S. Food and Drug Administration and therefore fall outside the usual oversight frameworks for safety, efficacy and manufacturing quality.
In its official notice, the board highlighted the practical consequence of that regulatory gap: without FDA review or inspection, it is difficult to verify the actual contents of such peptide products or to evaluate the risks they might pose to patients. The board underscored that peptides are short chains of amino acids that serve as building blocks for proteins and carry out important biological functions in the body, which further supports the need for rigorous oversight when they are intended for therapeutic use.
The board's guidance requires physicians to obtain and prescribe only drugs sourced from licensed suppliers that meet prescription-grade standards. The notice forbids the use or supply of non-FDA-approved peptides in any circumstance. The prohibition is not limited to physicians; it also applies to certified nurse midwives, nurse practitioners and physician assistants, who are constrained to prescribing medicines listed on approved formularies.
Addressing potential attempts to skirt the prohibition, the board stated that clinicians cannot evade professional or legal responsibility by labeling a product as "research-grade" or by relying on patient consent documents. Any clinician involvement in recommending, prescribing or administering such peptides, the board said, would violate their professional and legal obligations.
Separately from the state action, the FDA is scheduled to convene an advisory panel in July to consider whether licensed compounding pharmacies should be authorized to manufacture certain peptides. That federal review may influence future regulatory and supply dynamics, but the board's current instruction is explicit: providers in Alabama must adhere to prescription-grade sourcing and avoid non-FDA-approved peptides entirely.